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The Clinical Usefulness of 
18F-FDG
PET/CT for the Evaluation of 
Lymph Node Metastasis in Periorbital
Malignancies
Objective: The aim of this study was to assess the clinical role of 
18F-FDG
PET/CT for the evaluation of lymph node metastasis in periorbital malignancies,
compared with CT alone. 
Materials and Methods: We analyzed eighteen PET/CT and CT scans in 15
patients with biopsy-proven periorbital malignancies. We compared the diagnos-
tic capabilities of PET/CT and CT with regard to nodal metastasis by level-by-
level analysis and by N staging prediction. The reference standards were surgical
pathology (n = 7) from dissected lymph node specimens and the results from
radiological follow-up (n = 11, mean 20.5 months; range 10-52 months).
Moreover, any changes in patient care as prompted by PET/CT were recorded
and compared with treatment planning for CT alone. 
Results: PET/CT had a sensitivity of 100%, while CT had a sensitivity of 57%
(p = 0.03) for nodal metastasis by level-by-level analysis. PET/CT had a specifici-
ty of 97%, positive predictive value of 93%, negative predictive value of 100%,
and diagnostic accuracy of 98%, while the CT values for these same parameters
were 97%, 89%, 82%, and 84%, respectively. PET/CT correctly predicted N stag-
ing with an accuracy of 100%, while CT was only 83% accurate (p = 0.01).
Regarding the impact on patient care, the extent of surgery for regional lymph
nodes and the treatment decision were modified by PET/CT in 39% of patients. 
Conclusion: PET/CT could provide useful information in the management of
regional lymph node metastases in patients with periorbital malignancies. 
n periorbital malignancies, regional lymph node metastasis occurs
through lymphatic pathways from the upper or lower eyelids. Depending
on the site of the primary tumor, draining lymph nodes could be located
in the parotid area or cervical region (1, 2). The rate of regional metastasis has been
reported to be 10% to 24% in squamous cell carcinomas of the eyelid (3, 4) and 17%
to 28% in sebaceous carcinomas (4, 5).
In a previous study, investigators reported the pattern of regional lymph node
metastasis in patients with malignant tumors in the periorbital region (6). Four of
seven tumors (two squamous cell carcinomas, two sebaceous cell carcinomas) involv-
ing the medial half of the periorbital area exhibited lymphatic spread to the lymph
nodes around the parotid gland first, and then submandibular and upper cervical
lymph node spread. Proper management of regional metastasis is as important as
control of local recurrence in obtaining successful treatment outcomes in periorbital
malignancies. Surgical treatment for regional metastasis includes cervical lymph node
dissection with parotidectomy; therefore precise assessment of the extent of disease is
essential to treatment planning.
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IContrast-enhanced computed tomography (CT) and
magnetic resonance imaging (MRI) have been the mainstay
imaging modalities for the diagnosis and staging of primary
lesions, as well as regional lymph node metastasis, in
periorbital malignancies. Positron emission tomography
with 
18F-fluorodeoxyglucose integrated with computed
tomography (PET/CT) has been reported to be more
accurate than CT or MRI for the detection of malignant
tissues, while glucose uptake levels show a good correla-
tion with histological grading for head and neck cancers
(7). With regard to head and neck cancers, PET/CT has a
sensitivity of 98%, specificity of 92%, and accuracy of
94%, and its accuracy is higher than that seen with PET or
CT alone (8). In addition, PET/CT has the clear potential to
affect the care of patients with head and neck cancer (9). 
Because PET/CT has the potential for helping stage
patients with head and neck cancer, identifying responses
to non-surgical therapy, and allowing earlier detection of
recurrence, specific recommendations for its use should be
delineated to determine which patients will get cost-
effective benefits from undergoing PET/CT (10). For
example, our previous data showed that PET/CT imaging
does not provide additional information over laryngo-
scopic examination or CT at the initial tumor evaluation,
nor does it have a major impact on clinical decision-making
in patients with glottic cancer (11). 
However, little information is available concerning the
application of PET/CT in periorbital malignancies (12-16),
and the role of PET/CT in the evaluation of regional lymph
node metastasis has not been reported in any other study. 
The aim of the present study was to assess the diagnostic
efficacy of PET/CT for the evaluation of regional lymph
node metastasis in patients with periorbital malignancies
and to determine the impact of PET/CT on treatment
planning. 
MATERIALS AND METHODS
Subjects
The Institutional Review Board of the Samsung Medical
Center approved this study. Patient informed consent was
not required for this retrospective analysis, though
radiological examination-related informed consents were
obtained from all patients before PET/CT and CT were
performed. 
The inclusion criteria for this study were as follows: 1)
pathologically confirmed malignant tumor in the perior-
bital region we defined the periorbital region as the
upper and lower eyelid and their appendages, in addition
to the lacrimal glands, 2) both PET/CT and CT performed
in each patient, with the interval between the two studies
being less than one month. Based on these criteria, 15
cases of periorbital malignant tumors were retrieved from
the Samsung Medical Center Orbital Cancer Data Registry
for the period spanning 1996 to 2007. For these patients,
pathological diagnoses were reconfirmed through intra-
department consultations. 
Subject data are presented in Table 1. The mean patient
age was 55.3 years (range 28 to 79 years). Three patients
were male, and 12 were female. The eyelid was the most
commonly involved primary tumor site (11 cases, 73.3%);
other sites of involvement included the conjunctiva and
lacrimal gland. Pathological diagnoses included six
sebaceous carcinomas (40.4%), four malignant melanomas
(26.6%), two adenocarcinomas (13.3%), two adenoid
cystic carcinomas (13.3%), and one squamous cell
carcinoma (6.8%). Surgical treatment alone was performed
in 11 cases (73.4%), surgery with adjuvant radiotherapy in
two cases (13.3%), and radiotherapy alone in two cases
(13.3%). The median follow-up duration was 17.9 months
(range 3-52 months). Eleven patients (73.4%) have
survived without evidence of disease, whereas two patients
are still alive with disease, and two patients have died of
disease. A total of 18 PET/CT and CT scans were
performed in 15 cases. Most of the scans were performed
during the follow-up period (12 scans, 66.7%), and in
some cases (6 scans, 33.3%), the scans were done as part
of the initial diagnostic work-up. The reference standards
for PET/CT and CT were surgical pathology (n = 7) from
dissected lymph node specimens and data from radiologi-
cal follow-up (n = 11, duration 10-52 months, mean 20.5
months). Radiological follow-up included two or more
subsequent imaging studies (CT, MRI, or bone scans) for
suspected lesions during the follow-up period.
Contrast-Enhanced CT and 
18F-FDG PET/CT Scans
CT scans (LightSpeed Ultra or Ultra 16, GE, Milwaukee,
WI) were performed using the following parameters: 160
mAs, 120 KeV, section width of 3.75 mm, and table feed
of 8.75 mm per rotation. For contrast enhancement, 90 mL
of an iodinated contrast agent (Ultravist 300, Schering,
Berlin) was injected intravenously at 3 mL/sec using an
automated injector. The scan delay time was 30 seconds.
As for PET/CT scans, all patients fasted for at least six
hours prior to the examinations, which were performed
using a Discovery LS PET/CT scanner (GE Healthcare,
Milwaukee, WI). Whole body CT scanning was performed
using a continuous spiral technique with an 8-slice helical
CT with a gantry rotation speed of 0.8 sec. The CT scan
data were collected using the following parameters: 80
mAs, 140 KeV, section width of 5 mm, and table feed of 5
mm per rotation. No intravenous or oral contrast agents
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intravenous injection of 370 MBq 
18F-FDG, an emission
scan was performed from the thigh to the head at 5
minutes per frame, for a total of 45 minutes. The uptake
phase duration was 45 minutes. The attenuation-corrected
18F-FDG PET images from the CT data were reconstructed
with an ordered subset expectation maximization
algorithm (28 subsets, 2 iterations). The images were
displayed in a 128×128 matrix (pixel size = 4.29×4.29
mm, with a slice thickness of 4.25 mm). The separate CT
and PET scan data were accurately co-registered using
commercial software (eNTEGRA, Elgems, Haifa, Israel).
The standardized uptake values (SUVs) were acquired
using the attenuation-corrected images, the amount of
injected 
18F-FDG, the body weight of each patient, and the
cross-calibration factors between the 
18F-FDG PET and the
dose calibrator.
Data Analysis
For analysis, regional lymph nodes were divided into
lymph node levels (intra-parotid and peri-parotid lymph
node groups, levels I, IIa, IIb, III) based on the AJCC
staging manual (6th edition, 2002). The peri-parotid lymph
node group was defined to encompass the pre-auricular
lymph nodes and the infra-parotid lymph nodes.
Pathological data were available in 23 dissected node
levels, and radiological follow-up examination was used in
20 node levels. As a result, a total of 43 node levels were
assessed with CT and PET/CT scans in the present study. A
radiologist specializing in head and neck imaging reviewed
the CT scans, and a nuclear medicine physician reviewed
the PET/CT scans. Both of them were blinded to the
clinical and pathological information for the patients. 
The criteria for abnormal lymph nodes on CT included
spherical or conglomerated shape, enlarged size (> 1.5 cm
at levels I and II, > 1 cm at level III), or enhancement
pattern of contrast media. Regarding the PET/CT scans, the
nuclear medicine physician first reviewed the images to
evaluate for any abnormal FDG uptake in the salivary
glands and neck nodes by using the maximal uptake values
with intensity higher than that of surrounding tissues. The
interpretation was then revised based on the anatomical
FDG PET/CT for Lymph Node Metastasis Evaluation in Periorbital Malignancy
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Table 1. Characteristics of Subjects who had Undergone PET/CT and CT Scans (n = 15)
Interval 
Disease Status
Case 
Sex/Age  Site  Pathology 
between 
Tx 
Follow up  Clinical  Reference 
No.  Tx and  (mo)  Outcome  Standards 
PET/CT (mo) 
Local  Regional  Distant
Initial evaluation 
01  F/46  UE  Seb. ca  (+)  No  No  EX  18  NED  F/U 
02  F/53  LE  SCC  (+)  No  No  EX + PA + ND  16  NED  Pathology 
03  M/53  UE  Adenoca  (+)  No  No  RT  12  DOD  F/U 
04  F/28  Conj  Melanoma  (+)  No  No  OE  21  NED  F/U 
05  F/41  LG  ACC  (+)  No  (+)  Palliative RT  10  AWD  F/U
06* F/63  UE  Melanoma  (+)  No  No  OE + RT  15  Recur  F/U 
Follow-up setting 
01  F/71  UE  Seb. ca  29  No  No  No  No  52  NED  F/U 
02  F/79  UE  Seb. ca  240  No  IP  No  PA + ND  20  NED  Pathology 
03  M/65  UE  Seb. ca  20  No  IP  No  PA  10  NED  Pathology 
04  F/67  UE  Seb. ca  16  No  IP, PP, II  No  PA + ND  3  NED  Pathology 
05  M/56  UE  Seb. ca  11  No  IP, PP, II  No  PA + ND  8  NED  Pathology 
06  F/32  UE  ACC  3  (+)  No  No  EX  19  NED  F/U 
07  F/55  UE  Adenoca  21  No  IP  (+)  Palliative care  22  DOD  F/U 
08  F/42  Conj  Melanoma  17  (+)  PP  No  PA + ND + MX  Pathology 
29  No  No  No  No  24  NED  F/U 
09  F/65  Conj  Melanoma  19  No  IP  No  PA + ND  Pathology 
40  No  No  (+)  Palliative care  21  AWD  F/U 
10  F/63  UE  Melanoma  15  (+)  No  No  EX  12  NED  F/U 
Note.─ UE = upper eyelid, LE = lower eyelid, Conj = conjunctiva, LG = lacrimal gland, Seb. ca = sebaceous carcinoma, SCC = squamous cell carcinoma, 
Adenoca = adenocarcinoma , ACC = adenoid cystic carcinoma, Tx = treatment, IP = intra-parotid lymph nodes, PP = peri-parotid lymph nodes, II = upper
jugular cervical lymph nodes, EX = mass excision, PA = parotidectomy, ND = neck lymph node dissection, RT = radiation therapy, OE = wide excision of
tumor with orbital exenteration, MX = maxillectomy, NED = no evidence of disease, DOD = died of disease, AWD = alive with disease, F/U = follow up,
*This patient had follow-up PET/CT (number 10 in follow-up setting).information provided by the combined PET/CT images.
Treatment planning was addressed in the multidiscipli-
nary head and neck tumor conference along with the
results of imaging studies. To compare the diagnostic
accuracy of both imaging studies for regional metastasis,
pathological data in the cases of surgery (n = 7) or the
follow-up results of radiological evaluation (n = 11) were
used as a reference standard. Image findings were
confirmed by radiological follow-up alone for eleven scans,
with a mean follow-up duration of 20.5 months (range 10-
52 months).   
We compared the sensitivity (SN), specificity (SP),
positive predictive value (PPV), negative predictive value
(NPV), and diagnostic accuracy (DA) in predicting regional
lymph node metastasis on level-by-level analysis and N
staging. Statistical differences between the imaging modali-
ties were analyzed employing the McNemar test, and 95%
confidence levels were determined using Wilson’s method.
Two-tailed p-values less than 0.05 were considered statisti-
cally significant. The impact of PET/CT on patient care was
also assessed with regard to changes in the extent of
surgery or in treatment planning.
RESULTS
Diagnostic Values for Regional Lymph Node Metastasis
Primary tumor evaluation information was only
available in five of 18 scans; the tumors were diagnosed
correctly using PET/CT scans for the initial work-up in four
cases and in one recurrent case. SUVs in the primary
tumors ranged from 2.9 to 7.5 (median 4). In our series,
the maximum SUV ranged from 2.2 to 8.1 (mean 5.3) for
lymph node metastases from sebaceous carcinoma, and
from 2.0 to 38.7 from malignant melanoma. One patient
with adenocarcinoma lymphatic metastasis showed FDG
uptake in lymph nodes with maximum SUV = 18.7.
On the lymph node level-by-level analysis, a total of 43
node levels were assessed with CT and PET/CT (Table 2).
There were 14 malignant node levels, with seven intra-
parotid lymph nodes, three peri-parotid lymph nodes, one
level I lymph node group, and three level IIa lymph node
groups. Interestingly, metastasis to the cervical node levels
(I, II, III) was always coincident with metastasis to peri- or
intra-parotid nodes. CT had an SN of 57%, SP of 97%,
PPV of 89%, NPV of 82%, and DA of 84%. For PET/CT,
corresponding values were 100%, 97%, 93%, 100%, and
98%, respectively. PET/CT had a value of 100% for SN
and NPV. Of note, the difference in the sensitivity value
between CT and PET/CT was statistically significant, with
a p value of 0.03. 
In the prediction of N staging according to the AJCC
staging manual (6th edition, 2002), PET/CT showed 100%
accuracy (95% confidence interval: 82.4-100%), while CT
showed 83% accuracy (95% confidence interval: 60.7-
94.1%, p = 0.01). 
Impact of PET/CT on Patient Care
The extent of the surgical field for regional lymph nodes
was changed in the case of three PET/CT scans (3/18,
16.6%). In two of the three cases, intra-parotid metastatic
lymph nodes were detected on PET/CT, but not on CT. A
65-year-old male patient underwent eyelid and orbit
exenteration secondary to biopsy-proven sebaceous
carcinoma in the upper eyelid extending to the levator
Baek et al.
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Table 2. Diagnostic Values for Contrast-Enhanced CT and PET/CT with Regard to Regional Lymph Node Metastasis in Patients
with Periorbital Malignancies on Lymph Node Level-by-Level Analysis (n = 43 node levels)
LN Level CT PET/CT P
�
TP TN FP FN TP TN FP FN
Intra-parotid  5 061 207 070 0
Peri-parotid 1 0802 03 0800
Level I 1 040 001 031 0
Level IIa 1 060 203 060 0
Level IIb 0 030 000 030 0
Level III 0 010 000 010 0
Total 8281 6 14 281 0
Sensitivity (%) 57.1 (42.3 ~ 70.7) * .100 (91.7 ~ 100) 0.03
Specificity (%) 96.6 (86.3 ~ 99.2) 96.6 (86.3 ~ 99.2) NS
PPV (%) 88.9 (76.1 ~ 95.2) 93.3 (81.7 ~ 97.7) NS
NPV (%) 82.4 (68.5 ~ 90.9) .100 (91.7 ~ 100) NS
DA (%) 83.7 (70.0 ~ 91.8) 97.7 (87.9 ~ 99.5) NS
Note.─ LN level = lymph node level, TP = true positive, TN = true negative, FP = false positive, FN = false negative, PPV = positive predictive value, 
NPV = negative predictive value, DA = diagnostic accuracy, NS = not statistically significant * 95% CI = 95% confidence interval using Wilson’s method.
� Comparison of diagnostic values between CT and PET/CT using McNemar test.muscle and bulbar conjunctiva. After 16 months, a small
node was detected in the ipsilateral parotid area during a
follow-up visit. Contrast-enhanced CT scan showed no
abnormal mass lesion in the parotid area (Fig. 1). On the
contrary, PET/CT revealed a high glucose uptake lesion
with an SUV of 4.7 at the same site; lymph node metastasis
was strongly suspected. A parotidectomy was performed,
and metastatic sebaceous carcinoma was diagnosed in an
intra-parotid lymph node. Another 67-year-old female
patient was suspected of having recurrent sebaceous
carcinoma in the parotid area. Intra-parotid and peri-
parotid metastatic lymph nodes were equally detected on
CT and PET/CT, but the level II lymph node was
diagnosed as containing malignancy only on PET/CT. As a
result, the surgical extent was expanded into the level II
area; a metastatic lymph node was demonstrated patholog-
ically. Another 56-year-old male patient who had
undergone orbital exenteration for sebaceous carcinoma in
the upper eyelid was suspected of having regional
recurrence in the ipsilateral parotid area (Fig. 2). On CT, a
0.8 cm sized lymph node was detected just behind the
angle of the mandible, but the contrast enhancement was
not definite, and the lymph node maintained an oval
shape, so a radiologist diagnosed it as an insignificant
lymph node. However, PET/CT showed an asymmetrical
lesion with an SUV of 2.2, suggesting metastasis. As a
FDG PET/CT for Lymph Node Metastasis Evaluation in Periorbital Malignancy
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Fig.1. 65-year-old male patient with sebaceous carcinoma in upper eyelid. 
A. On contrast-enhanced CT, no definite lesion is detected around parotid gland. 
B, C. On PET/CT, malignant lesion with high glucose uptake of SUV 4.7 is diagnosed at same site (arrows). According to fused image,
malignant lesion is located around parotid gland. 
ABC
Fig. 2. 56-year-old male patient with sebaceous carcinoma in upper eyelid. 
A. On contrast-enhanced CT, upper jugular lymph node behind angle of mandible is considered benign, with pattern of low enhancement
and oval shape (arrow). 
B, C. On PET/CT, same lesion showed asymmetrical glucose uptake with SUV 2.2 and is diagnosed as metastatic lymph node (arrows).
As result, surgical fields were extended to include specific lymph node, which was pathologically proven to have metastatic lesion.
ABCresult, the extent of surgery was changed to include the
above lymph node group, which proved to have metastasis
on pathology.
Three patients in this study had distant metastases that
were first detected by PET/CT. The pathology of the
primary tumors included an adenocarcinoma in the upper
eyelid, a melanoma in the conjunctiva, and an adenoid
cystic carcinoma in the upper eyelid. PET/CT during the
follow-up period detected distant metastases in the brain,
pancreas, liver, stomach, or cervical spine, so treatment
plans were changed to palliative care, including palliative
chemotherapy or radiotherapy. 
In one case (Case No. 1 in Table 1), a malignant lymph
node was suspected in the peri-parotid region on CT,
contradictory to the PET/CT findings, which suggested a
benign lymph node. Surgical treatment was withheld until
after confirmation using fine needle aspiration biopsy, and
the patient still shows no evidence of disease in that area
after 18 months of follow-up. 
As shown in Table 3, PET/CT affected treatment by
correctly modifying the surgical extent or treatment
decision in seven cases (38.8%).   
DISCUSSION
Basal cell carcinoma and squamous cell carcinoma are
the most common malignancies arising in the periorbital
region, with malignant melanoma and sebaceous
carcinoma occurring less frequently (2). As in most solid
tumors, the presence of regional lymph node metastasis
affects treatment outcomes and prognosis profoundly.
Regional metastases from periorbital malignancies spread
through the lymphatic system, so careful evaluation of the
regional lymph nodes is important. In this study, we
included the three conjunctival melanomas for analysis,
because they showed frequent metastasis to regional
lymph nodes and distant sites, similar to other periorbital
cancers.
In a previous case study (6), our group observed no
direct tumor drainage to the submandibular lymph nodes-
even from primary tumors located on the medial portion of
the eyelid-without initial metastasis to the lymph nodes
around the parotid gland (first echelon lymph node); this is
concordant with the results of the present study.    
CT, with its high sensitivity (93%) (17), has been the
mainstay imaging modality for diagnosing periorbital
malignancies. However, the sensitivity of CT in the present
study was as low as 57%. This is attributable to false
negative lesions at peri-parotid and intra-parotid sites.
Some of these lesions were interpreted as inflammatory
hyperplasia or infected cysts due to the absence of distinct
features of malignant parotid tumors, such as lobular or
irregular contour of the mass or ill-defined tumor margin.
According to recent reports (18, 19), the higher sensitivity
and diagnostic accuracy of PET/CT endows it with many
advantages over CT alone in managing malignancies
around the salivary gland, especially high-grade types. The
present study also showed that PET/CT was effective in
detecting lymphatic spread to the parotid region and
cervical nodes in the setting of periorbital malignancies. 
Among the 15 subjects enrolled in this study, seven had
true regional lymph node metastasis (46.7%).
Interestingly, all seven had recurrent metastasis in regional
lymph nodes. The duration between the treatment of the
primary tumor and the detection of regional recurrence
ranged from 11 months to 240 months. On standard
follow-up, PET/CT accurately diagnosed seven cases of
regional recurrence. However, CT alone misdiagnosed two
cases as negative for recurrence. 
Distant metastases occurred in three cases. The metasta-
tic sites were diverse, including brain, cervical spine,
pancreas, and lung. Distant metastasis was detected in the
cervical spine in one patient using PET/CT as an initial
evaluation, and palliative treatment instead of curative
surgery was implemented as a result.  
The higher sensitivity of PET/CT vindicated it as a useful
screening method in the evaluation of regional lymph node
metastasis, particularly in the follow-up setting. PET/CT
had a higher NPV (100%) than did CT alone (82.4%),
although this difference was not statistically significant.
Prediction of N stage was also more reliable with PET/CT
than with CT alone. Therefore, PET/CT can provide more
accurate information about prognosis through revision of
N staging of periorbital malignancies. 
In practice, how much diagnostic methods affect
treatment decision-making is of great concern for
clinicians. In this study, PET/CT had a positive impact on
patient care by correctly modifying the treatment plan in
approximately 40% of the patients.
Errors in interpretation of abnormal lymph node FDG
uptake may be instigated in cases of larygopharyngeal
inflammation. However, several diagnostic clues help
differentiate lymph nodes metastasis from inflammation.
Baek et al.
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Table 3. Impact on Patient Care: Contrast-enhanced CT
versus PET/CT (n = 18 CT and PET/CT scans)
Changes in Patient Care 
by PET/CT
Extent of surgery for neck nodes 3/18 (16.6%)
Change in treatment plan  4/18 (22.2%)
Total 7/18 (38.8%)First, asymmetrical abnormal lymph node uptake strongly
suggests metastasis, because inflammation frequently
causes bilateral FDG uptake. Malignant tumors in the
periorbital area have lymph nodes around the parotid area
as the first-echelon nodal group (6). Thus, without
abnormal uptake in the lymph nodes around the parotid
area, the increase of FDG uptake in the upper cervical
lymph nodes, which commonly occurs in laryngo-pharyn-
gitis, may be demarcated from the lymph node metastasis
of periorbital malignancy. In addition, an SUV of 2.0 in
lymph nodes can be used as a cut-off value in determining
the presence of metastasis, based on our results.
Our study has some limitations. First, this was a
retrospective analysis with a small number of cases.
Prospective study with a larger number of cases is needed
to fully assess the role of PET/CT in the management of
lymph node metastasis in the setting of periorbital
malignancies. Second, heterogeneity of the neoplasms in
the present study prompted the question of the
radiographic equivalence of different tumors on PET/CT.
Characteristics of FDG uptake may vary among different
pathologies, and it would be premature to claim that
PET/CT is equally effective in all periorbital malignancies.
Third, our data does not answer the question of when to
perform PET/CT in the setting of periorbital malignancies,
though our results showed that PET/CT provided more
accurate information about nodal status when lymphatic
metastases were suspected. These questions demand a
further study enrolling a large number of patients. 
Nevertheless, this study showed that PET/CT could
provide more accurate diagnostic information regarding
lymph node status. Furthermore, it was more reliable in
predicting N staging in the setting of periorbital malignan-
cies than was CT alone. PET/CT also had a significant
impact on therapeutic decision-making. 
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